HANMI PHARM.
HANMI PHARM, officially known as Hanmi Pharmaceutical Co., Ltd., is a leading player in the global pharmaceutical industry, headquartered in KP. Founded in 1973, the company has established a strong presence in major operational regions, including Asia, Europe, and North America. Specialising in innovative drug development, HANMI PHARM focuses on areas such as oncology, diabetes, and autoimmune diseases, offering unique products that leverage advanced biopharmaceutical technologies. With a commitment to research and development, HANMI PHARM has achieved significant milestones, including the successful launch of several proprietary drugs. The company is recognised for its robust pipeline and strategic partnerships, positioning it as a formidable competitor in the market. Through its dedication to quality and innovation, HANMI PHARM continues to make strides in improving patient outcomes worldwide.
DitchCarbon Score
How does HANMI PHARM.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
HANMI PHARM.'s score of 22 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
HANMI PHARM.'s reported carbon emissions
In 2023, HANMI PHARM. reported total carbon emissions of approximately 115,200,000 kg CO2e from Scope 1 and 2, alongside significant Scope 3 emissions of about 82,555,000 kg CO2e. This marks a continued commitment to transparency in their emissions reporting, with a total of approximately 197,755,000 kg CO2e emitted across all scopes. Over the years, HANMI PHARM. has demonstrated a trend of reducing its emissions. In 2022, the company recorded total emissions of about 60,118,000 kg CO2e for Scope 1 and 2, and approximately 40,801,000 kg CO2e for Scope 3. This indicates a proactive approach to managing and mitigating their carbon footprint. The company has not publicly disclosed specific reduction targets or initiatives, such as those aligned with the Science Based Targets initiative (SBTi). However, their ongoing emissions tracking reflects an awareness of climate impact and a commitment to sustainability within the pharmaceutical industry. Overall, HANMI PHARM.'s emissions data highlights the importance of continuous improvement in carbon management practices, as they navigate the challenges of reducing their environmental impact while maintaining operational efficiency.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 13,523,000 | 00,000,000 | 00,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 58,287,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
HANMI PHARM. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
